- Home
- TPIC vs CABA Comparison
TPIC vs CABA Comparison
Compare TPIC & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPIC
- CABA
- Stock Information
- Founded
- TPIC 1968
- CABA 2017
- Country
- TPIC United States
- CABA United States
- Employees
- TPIC N/A
- CABA N/A
- Industry
- TPIC Industrial Machinery/Components
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TPIC Industrials
- CABA Health Care
- Exchange
- TPIC Nasdaq
- CABA Nasdaq
- Market Cap
- TPIC 207.8M
- CABA 210.0M
- IPO Year
- TPIC 2016
- CABA 2019
- Fundamental
- Price
- TPIC $2.17
- CABA $3.03
- Analyst Decision
- TPIC Hold
- CABA Strong Buy
- Analyst Count
- TPIC 5
- CABA 10
- Target Price
- TPIC $4.49
- CABA $28.50
- AVG Volume (30 Days)
- TPIC 857.6K
- CABA 1.1M
- Earning Date
- TPIC 11-07-2024
- CABA 11-14-2024
- Dividend Yield
- TPIC N/A
- CABA N/A
- EPS Growth
- TPIC N/A
- CABA N/A
- EPS
- TPIC N/A
- CABA N/A
- Revenue
- TPIC $1,301,740,000.00
- CABA N/A
- Revenue This Year
- TPIC N/A
- CABA N/A
- Revenue Next Year
- TPIC $23.03
- CABA N/A
- P/E Ratio
- TPIC N/A
- CABA N/A
- Revenue Growth
- TPIC N/A
- CABA N/A
- 52 Week Low
- TPIC $1.90
- CABA $2.96
- 52 Week High
- TPIC $5.75
- CABA $26.35
- Technical
- Relative Strength Index (RSI)
- TPIC 28.13
- CABA 32.06
- Support Level
- TPIC $2.11
- CABA $4.33
- Resistance Level
- TPIC $2.53
- CABA $4.49
- Average True Range (ATR)
- TPIC 0.31
- CABA 0.38
- MACD
- TPIC -0.10
- CABA -0.07
- Stochastic Oscillator
- TPIC 3.63
- CABA 3.91
About TPIC TPI Composites Inc.
TPI Composites Inc is engaged in manufacturing composite wind blades. The company operates in wind energy and transportation industries where it manufactures structures for a bus, rail, theme parks, and trucks. Geographically the segments are divided into the U.S, Asia, Mexico, EMEA and India where the Mexico segment derives a majority of revenue.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.